New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
08:11 EDTOCLSOculus provides second half CY12 business update
Oculus Innovative Sciences, provided a market update for the second half of 2012. Financial Update/EBITDAS Profitability Expected During FY14. Total revenue was $8.6M in the six months ended September 30, compared to $6.6M in the same period last year with product revenue growing at 32% over the same period last year. Operating loss minus non-cash expenses, or EBITDAS, for these six months was $235,000 compared to $1.2M in the same period last year. If adjusted for one-time severance costs of $410,000 relating to the transaction with Oculus partner, More Pharma, Oculus would have been EBITDAS profitable for the first half of FY13. The company's cash position as of September 30 was $8.3M.
News For OCLS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
08:13 EDTOCLSOculus receives CE Mark for Microcyn-based atopic dermatitis Hydrogel
Oculus Innovative Sciences announced the issuance of a new CE Mark in Europe for Microcyn-based Pediacyn Hydrogel. Pediacyn Hydrogel is indicated for the care of lesions associated with atopic dermatitis by assisting with moistening while forming a protective barrier against physical, chemical and microbial invasion of the atopic dermatitis lesions.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use